Efficacy of the combined therapy with Rituximab plus Cyclophosphamide versus Cyclophosphamide as Monotherapy in Systemic Sclerosis-Associated Interstitial Lung Disease

被引：0
|
作者：
Tejeda-Andrade, C. F. [1 ]
Villalpando-Gomez, Y. [1 ]
Gamez-Nava, J., I [1 ]
Castro-Lizano, N. [1 ]
Rocha-Munoz, A. D. [1 ]
Cardona, Munoz E. G. [1 ]
Gonzalez-Lopez, L. [1 ]
机构：
[1] Univ Guadalajara, CUCS, Unidad Invest Cardiovasc, Guadalajara, Jalisco, Mexico
来源：
JOURNAL OF RHEUMATOLOGY | 2011年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1193 / 1193
页数：1
相关论文
共 50 条
  • [21] Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: Comment on the article by Yoo
    Daoussis, Dimitrios
    Andonopoulos, Andrew P.
    RHEUMATOLOGY INTERNATIONAL, 2011, 31 (06) : 841 - 842
  • [22] Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
    Bergamasco, Aurore
    Hartmann, Nadine
    Wallace, Laura
    Verpillat, Patrice
    CLINICAL EPIDEMIOLOGY, 2019, 11 : 257 - 273
  • [23] Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: Comment on the article by Yoo
    Dimitrios Daoussis
    Andrew P. Andonopoulos
    Rheumatology International, 2011, 31 : 841 - 842
  • [24] Treatment for systemic sclerosis-associated interstitial lung disease
    Roofeh, David
    Lescoat, Alain
    Khanna, Dinesh
    CURRENT OPINION IN RHEUMATOLOGY, 2021, 33 (03) : 240 - 248
  • [25] EFFICACY AND SAFETY OF LONG TERM CYCLOPHOSPHAMIDE TREATMENT FOR INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS
    Kwon, H. M.
    Karig, E. H.
    Go, D. J.
    Park, J. K.
    Lee, E. Y.
    Song, Y. W.
    Lee, H. -J.
    Lee, E. B.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 1011 - 1011
  • [26] Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
    Andreasson, Kristofer
    Wuttge, Dirk M.
    Wollheim, Frank A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (16): : 1595 - 1596
  • [27] Management of systemic sclerosis-associated interstitial lung disease
    Roofeh, David
    Jaafar, Sara
    Vummidi, Dharshan
    Khanna, Dinesh
    CURRENT OPINION IN RHEUMATOLOGY, 2019, 31 (03) : 241 - 249
  • [28] Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
    Distler, Oliver
    Highland, Kristin B.
    Gahlemann, Martina
    Azuma, Arata
    Fischer, Aryeh
    Mayes, Maureen D.
    Raghu, Ganesh
    Sauter, Wiebke
    Girard, Mannaig
    Alves, Margarida
    Clerisme-Beaty, Emmanuelle
    Stowasser, Susanne
    Tetzlaff, Kay
    Kuwana, Masataka
    Maher, Toby M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (26): : 2518 - 2528
  • [29] SAFETY AND EFFICACY OF COMBINED B CELL-DEPLETION THERAPY WITH RITUXIMAB AND CYCLOPHOSPHAMIDE IN SYSTEMIC SCLEROSIS
    Picco, L.
    De Marchi, G.
    Di Poi, E.
    Masolini, P.
    De Vita, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (02) : S42 - S43
  • [30] Treatment of systemic sclerosis-associated interstitial lung disease
    Prasse, A.
    Bonella, F.
    Mueller-Ladner, U.
    Witte, T.
    Hunzelmann, N.
    Distler, J.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (03): : 294 - 303
12345